<p>Larimar Therapeutics, Inc.（納斯達克代碼：LRMR - 獲取免費報告）週五股價上漲 8.2%，在 Wedbush 將該股目標價從 12.00 美元上調至 13.00 美元后。Wedbush 目前對該股的評級為跑贏大盤。Larimar Therapeutics 的股價最高達到 4.83 美元，最後交易價為 4.8350 美元。在午盤交易中，共成交 1,065,757 股，較平均交易量 4,496,090 股下降了 76%。該股此前收盤價為 4.47 美元。</p>
<p>獲取 <strong>Larimar Therapeutics</strong> 的提醒：</p>
<ul>
<li>根據表現排名的最佳股票選擇 AI</li>
</ul>
<p>其他一些券商最近也對 LRMR 發表了評論。Leerink Partners 在 1 月 5 日的研究報告中將 Larimar Therapeutics 的股票評級上調至 “強買入”。Weiss Ratings 在 1 月 22 日的報告中重申了對 Larimar Therapeutics 的 “賣出（d-）” 評級。花旗集團在 2 月 25 日的研究報告中將 Larimar Therapeutics 的目標價從 12.00 美元上調至 14.00 美元，並給予該公司 “買入” 評級。最後，Lifesci Capital 在 2 月 24 日的研究報告中將 Larimar Therapeutics 的評級上調至 “強買入”。兩位股票研究分析師對該股給予了強買入評級，七位分析師給予了買入評級，一位分析師給予了賣出評級。根據 MarketBeat 的數據，Larimar Therapeutics 目前的共識評級為 “買入”，平均目標價為 16.43 美元。</p>
<p><strong>獲取我們最新的 LRMR 股票分析</strong></p>
<h2>Larimar Therapeutics 的內部買賣</h2>
<p>在 Larimar Therapeutics 的其他新聞中，董事 James E. Flynn 在 2 月 27 日的交易中購買了 5,000,000 股該公司的股票。該股票的平均購買價格為每股 5.00 美元，總交易額為 25,000,000.00 美元。交易後，該董事在公司持有 10,622,957 股，價值 53,114,785 美元。該交易使其持股增加了 88.92%。該交易已在向 SEC 提交的文件中披露，文件可通過 SEC 網站獲取。內部人士持有該公司 4.50% 的股份。</p>
<h2>機構資金流入和流出</h2>
<p>幾家大型投資者最近對該公司的持倉進行了調整。Deerfield Management Company L.P.在第三季度將其在 Larimar Therapeutics 的股份增加了 44.2%。Deerfield Management Company L.P.目前持有 30,606,974 股該公司的股票，價值 98,861,000 美元，在此期間又購買了 9,375,000 股。Opaleye Management Inc.在第二季度將其在 Larimar Therapeutics 的持倉增加了 114.7%。Opaleye Management Inc.目前持有 4,110,000 股該公司的股票，價值 11,878,000 美元，在此期間又購買了 2,195,923 股。Woodline Partners LP 在第三季度將其在 Larimar Therapeutics 的持倉增加了 160.6%。Woodline Partners LP 目前持有 1,622,850 股該公司的股票，價值 5,242,000 美元，在上個季度又購買了 1,000,168 股。AIGH Capital Management LLC 在第四季度將其在 Larimar Therapeutics 的持倉增加了 100.0%。AIGH Capital Management LLC 目前持有 2,000,000 股該公司的股票，價值 7,620,000 美元，在此期間又購買了 1,000,000 股。最後，Blue Owl Capital Holdings LP 在第四季度將其在 Larimar Therapeutics 的持倉增加了 16.6%。Blue Owl Capital Holdings LP 目前持有 6,823,690 股該公司的股票，價值 25,998,000 美元，在此期間又購買了 970,650 股。91.92% 的股票由對沖基金和其他機構投資者持有。</p>
<h2>Larimar Therapeutics 股價上漲 8.4%</h2>
<p>該公司的 50 日移動平均價格為 3.93 美元，200 日移動平均價格為 3.91 美元。該股市值為 5.02 億美元，市盈率為-2.55，貝塔值為 0.91。</p>
<p>Larimar Therapeutics（納斯達克代碼：LRMR - 獲取免費報告）最後一次公佈季度財報是在 3 月 23 日。該公司報告季度每股收益（EPS）為（0.73 美元），低於共識預期的（0.43 美元）0.30 美元。整體來看，分析師預計 Larimar Therapeutics, Inc.在本年度的每股收益將為-1.15 美元。</p>
<h2>關於 Larimar Therapeutics</h2>
<p>（獲取免費報告）</p>
<p>Larimar Therapeutics, Inc.是一家臨牀階段的生物技術公司，專注於利用其新型細胞穿透肽技術平台開發罕見疾病的治療方案。其主要產品候選藥物 CTI-1601 目前正在進行針對弗里德里希共濟失調的第二階段 OLE 臨牀試驗，這是一種罕見的、進行性且致命的遺傳疾病。Larimar Therapeutics, Inc.總部位於賓夕法尼亞州巴拉金威德。</p>
<h2>另見</h2>
<ul>
<li>五隻我們更看好的股票，勝過 Larimar Therapeutics</li>
</ul>
<p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
<h2>你現在應該投資 1,000 美元在 Larimar Therapeutics 嗎？</h2>
<p>在你考慮 Larimar Therapeutics 之前，你需要聽聽這個。</p>
<p>MarketBeat 跟蹤華爾街頂級評級和表現最佳的研究分析師及其每日推薦的股票。MarketBeat 已識別出五隻頂級分析師正在悄悄向客户推薦的股票，以便在更廣泛的市場注意到之前購買...而 Larimar Therapeutics 並不在名單上。</p>
<p>雖然 Larimar Therapeutics 目前在分析師中獲得了買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

LRMR

<p>Larimar Therapeutics（納斯達克代碼：LRMR）股價上漲 8.2%，在 Wedbush 將其目標價從 12.00 美元上調至 13.00 美元，並維持 “跑贏大盤” 評級後，該股交易價格為 4.83 美元，交易量顯著下降。其他券商也發佈了評級，普遍評級為 “買入”，平均目標價為 16.43 美元。內部交易方面，董事 James E. Flynn 購買了 500 萬股。機構投資者增加了持股比例，91.92% 的股份由對沖基金持有。該公司專注於罕見疾病的治療，其主要產品正在進行臨牀試驗</p>

<p>Larimar Therapeutics, Inc. (NASDAQ:LRMR - Get Free Report) shares shot up 8.2% on Friday after Wedbush raised their price target on the stock from $12.00 to $13.00. Wedbush currently has an outperform rating on the stock. Larimar Therapeutics traded as high as $4.83 and last traded at $4.8350. 1,065,757 shares were traded during mid-day trading, a decline of 76% from the average session volume of 4,496,090 shares. The stock had previously closed at $4.47.</p>
<div class="lb-trans"><p>Larimar Therapeutics, Inc.（納斯達克代碼：LRMR - 獲取免費報告）週五股價上漲 8.2%，在 Wedbush 將該股目標價從 12.00 美元上調至 13.00 美元后。Wedbush 目前對該股的評級為跑贏大盤。Larimar Therapeutics 的股價最高達到 4.83 美元，最後交易價為 4.8350 美元。在午盤交易中，共成交 1,065,757 股，較平均交易量 4,496,090 股下降了 76%。該股此前收盤價為 4.47 美元。</p>
</div><p>Get <strong>Larimar Therapeutics</strong> alerts:</p>
<div class="lb-trans"><p>獲取 <strong>Larimar Therapeutics</strong> 的提醒：</p>
</div><ul>
<li>The Best AI for Picking Stocks, Ranked by Performance</li>
</ul>
<div class="lb-trans"><ul>
<li>根據表現排名的最佳股票選擇 AI</li>
</ul>
</div><p>A number of other brokerages have also recently commented on LRMR. Leerink Partners upgraded shares of Larimar Therapeutics to a &#34;strong-buy&#34; rating in a research note on Monday, January 5th. Weiss Ratings reaffirmed a &#34;sell (d-)&#34; rating on shares of Larimar Therapeutics in a report on Thursday, January 22nd. Citigroup lifted their price target on Larimar Therapeutics from $12.00 to $14.00 and gave the company a &#34;buy&#34; rating in a research report on Wednesday, February 25th. Finally, Lifesci Capital upgraded Larimar Therapeutics to a &#34;strong-buy&#34; rating in a research note on Tuesday, February 24th. Two equities research analysts have rated the stock with a Strong Buy rating, seven have issued a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat, Larimar Therapeutics currently has a consensus rating of &#34;Buy&#34; and an average price target of $16.43.</p>
<div class="lb-trans"><p>其他一些券商最近也對 LRMR 發表了評論。Leerink Partners 在 1 月 5 日的研究報告中將 Larimar Therapeutics 的股票評級上調至 “強買入”。Weiss Ratings 在 1 月 22 日的報告中重申了對 Larimar Therapeutics 的 “賣出（d-）” 評級。花旗集團在 2 月 25 日的研究報告中將 Larimar Therapeutics 的目標價從 12.00 美元上調至 14.00 美元，並給予該公司 “買入” 評級。最後，Lifesci Capital 在 2 月 24 日的研究報告中將 Larimar Therapeutics 的評級上調至 “強買入”。兩位股票研究分析師對該股給予了強買入評級，七位分析師給予了買入評級，一位分析師給予了賣出評級。根據 MarketBeat 的數據，Larimar Therapeutics 目前的共識評級為 “買入”，平均目標價為 16.43 美元。</p>
</div><p><strong>Get Our Latest Stock Analysis on LRMR</strong></p>
<div class="lb-trans"><p><strong>獲取我們最新的 LRMR 股票分析</strong></p>
</div><h2>Insider Buying and Selling at Larimar Therapeutics</h2>
<div class="lb-trans"><h2>Larimar Therapeutics 的內部買賣</h2>
</div><p>In other Larimar Therapeutics news, Director James E. Flynn purchased 5,000,000 shares of the company's stock in a transaction dated Friday, February 27th. The stock was purchased at an average price of $5.00 per share, for a total transaction of $25,000,000.00. Following the transaction, the director owned 10,622,957 shares in the company, valued at $53,114,785. The trade was a 88.92% increase in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Insiders own 4.50% of the company's stock.</p>
<div class="lb-trans"><p>在 Larimar Therapeutics 的其他新聞中，董事 James E. Flynn 在 2 月 27 日的交易中購買了 5,000,000 股該公司的股票。該股票的平均購買價格為每股 5.00 美元，總交易額為 25,000,000.00 美元。交易後，該董事在公司持有 10,622,957 股，價值 53,114,785 美元。該交易使其持股增加了 88.92%。該交易已在向 SEC 提交的文件中披露，文件可通過 SEC 網站獲取。內部人士持有該公司 4.50% 的股份。</p>
</div><h2>Institutional Inflows and Outflows</h2>
<div class="lb-trans"><h2>機構資金流入和流出</h2>
</div><p>Several large investors have recently made changes to their positions in the business. Deerfield Management Company L.P. increased its stake in shares of Larimar Therapeutics by 44.2% during the third quarter. Deerfield Management Company L.P. now owns 30,606,974 shares of the company's stock valued at $98,861,000 after buying an additional 9,375,000 shares during the period. Opaleye Management Inc. increased its position in Larimar Therapeutics by 114.7% during the 2nd quarter. Opaleye Management Inc. now owns 4,110,000 shares of the company's stock valued at $11,878,000 after purchasing an additional 2,195,923 shares during the period. Woodline Partners LP raised its holdings in Larimar Therapeutics by 160.6% in the 3rd quarter. Woodline Partners LP now owns 1,622,850 shares of the company's stock worth $5,242,000 after purchasing an additional 1,000,168 shares in the last quarter. AIGH Capital Management LLC lifted its position in shares of Larimar Therapeutics by 100.0% in the 4th quarter. AIGH Capital Management LLC now owns 2,000,000 shares of the company's stock worth $7,620,000 after purchasing an additional 1,000,000 shares during the period. Finally, Blue Owl Capital Holdings LP lifted its position in shares of Larimar Therapeutics by 16.6% in the 4th quarter. Blue Owl Capital Holdings LP now owns 6,823,690 shares of the company's stock worth $25,998,000 after purchasing an additional 970,650 shares during the period. 91.92% of the stock is owned by hedge funds and other institutional investors.</p>
<div class="lb-trans"><p>幾家大型投資者最近對該公司的持倉進行了調整。Deerfield Management Company L.P.在第三季度將其在 Larimar Therapeutics 的股份增加了 44.2%。Deerfield Management Company L.P.目前持有 30,606,974 股該公司的股票，價值 98,861,000 美元，在此期間又購買了 9,375,000 股。Opaleye Management Inc.在第二季度將其在 Larimar Therapeutics 的持倉增加了 114.7%。Opaleye Management Inc.目前持有 4,110,000 股該公司的股票，價值 11,878,000 美元，在此期間又購買了 2,195,923 股。Woodline Partners LP 在第三季度將其在 Larimar Therapeutics 的持倉增加了 160.6%。Woodline Partners LP 目前持有 1,622,850 股該公司的股票，價值 5,242,000 美元，在上個季度又購買了 1,000,168 股。AIGH Capital Management LLC 在第四季度將其在 Larimar Therapeutics 的持倉增加了 100.0%。AIGH Capital Management LLC 目前持有 2,000,000 股該公司的股票，價值 7,620,000 美元，在此期間又購買了 1,000,000 股。最後，Blue Owl Capital Holdings LP 在第四季度將其在 Larimar Therapeutics 的持倉增加了 16.6%。Blue Owl Capital Holdings LP 目前持有 6,823,690 股該公司的股票，價值 25,998,000 美元，在此期間又購買了 970,650 股。91.92% 的股票由對沖基金和其他機構投資者持有。</p>
</div><h2>Larimar Therapeutics Trading Up 8.4%</h2>
<div class="lb-trans"><h2>Larimar Therapeutics 股價上漲 8.4%</h2>
</div><p>The business's 50 day moving average price is $3.93 and its two-hundred day moving average price is $3.91. The stock has a market cap of $502.00 million, a P/E ratio of -2.55 and a beta of 0.91.</p>
<div class="lb-trans"><p>該公司的 50 日移動平均價格為 3.93 美元，200 日移動平均價格為 3.91 美元。該股市值為 5.02 億美元，市盈率為-2.55，貝塔值為 0.91。</p>
</div><p>Larimar Therapeutics (NASDAQ:LRMR - Get Free Report) last announced its quarterly earnings data on Monday, March 23rd. The company reported ($0.73) EPS for the quarter, missing the consensus estimate of ($0.43) by ($0.30). As a group, analysts expect that Larimar Therapeutics, Inc. will post -1.15 earnings per share for the current year.</p>
<div class="lb-trans"><p>Larimar Therapeutics（納斯達克代碼：LRMR - 獲取免費報告）最後一次公佈季度財報是在 3 月 23 日。該公司報告季度每股收益（EPS）為（0.73 美元），低於共識預期的（0.43 美元）0.30 美元。整體來看，分析師預計 Larimar Therapeutics, Inc.在本年度的每股收益將為-1.15 美元。</p>
</div><h2>About Larimar Therapeutics</h2>
<div class="lb-trans"><h2>關於 Larimar Therapeutics</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（獲取免費報告）</p>
</div><p>Larimar Therapeutics, Inc, a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich's ataxia, a rare, progressive and fatal genetic disease. Larimar Therapeutics, Inc is based in Bala Cynwyd, Pennsylvania.</p>
<div class="lb-trans"><p>Larimar Therapeutics, Inc.是一家臨牀階段的生物技術公司，專注於利用其新型細胞穿透肽技術平台開發罕見疾病的治療方案。其主要產品候選藥物 CTI-1601 目前正在進行針對弗里德里希共濟失調的第二階段 OLE 臨牀試驗，這是一種罕見的、進行性且致命的遺傳疾病。Larimar Therapeutics, Inc.總部位於賓夕法尼亞州巴拉金威德。</p>
</div><h2>See Also</h2>
<div class="lb-trans"><h2>另見</h2>
</div><ul>
<li>Five stocks we like better than Larimar Therapeutics</li>
</ul>
<div class="lb-trans"><ul>
<li>五隻我們更看好的股票，勝過 Larimar Therapeutics</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Larimar Therapeutics Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1,000 美元在 Larimar Therapeutics 嗎？</h2>
</div><p>Before you consider Larimar Therapeutics, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考慮 Larimar Therapeutics 之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Larimar Therapeutics wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 跟蹤華爾街頂級評級和表現最佳的研究分析師及其每日推薦的股票。MarketBeat 已識別出五隻頂級分析師正在悄悄向客户推薦的股票，以便在更廣泛的市場注意到之前購買...而 Larimar Therapeutics 並不在名單上。</p>
</div><p>While Larimar Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 Larimar Therapeutics 目前在分析師中獲得了買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

Larimar Therapeutics（納斯達克股票代碼：LRMR）在分析師上調評級後，股價上漲了 8.2%